Bank of Montreal Can Sells 25,162 Shares of Thermo Fisher Scientific Inc. $TMO

Bank of Montreal Can lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.3% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 558,849 shares of the medical research company’s stock after selling 25,162 shares during the quarter. Bank of Montreal Can owned approximately 0.15% of Thermo Fisher Scientific worth $226,591,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. South Dakota Investment Council grew its position in Thermo Fisher Scientific by 411.5% in the 2nd quarter. South Dakota Investment Council now owns 40,952 shares of the medical research company’s stock valued at $16,604,000 after acquiring an additional 32,946 shares during the last quarter. Meridian Management Co. grew its position in Thermo Fisher Scientific by 91.0% in the 2nd quarter. Meridian Management Co. now owns 10,166 shares of the medical research company’s stock valued at $4,122,000 after acquiring an additional 4,844 shares during the last quarter. Tredje AP fonden grew its position in Thermo Fisher Scientific by 44.6% in the 2nd quarter. Tredje AP fonden now owns 201,971 shares of the medical research company’s stock valued at $81,891,000 after acquiring an additional 62,279 shares during the last quarter. TIAA Trust National Association grew its position in Thermo Fisher Scientific by 10.5% in the 2nd quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock valued at $50,256,000 after acquiring an additional 11,817 shares during the last quarter. Finally, Versor Investments LP bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $271,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.4%

Shares of NYSE TMO opened at $565.19 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock has a market capitalization of $213.42 billion, a P/E ratio of 32.65, a price-to-earnings-growth ratio of 3.27 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The business has a fifty day moving average price of $512.35 and a 200 day moving average price of $458.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the sale, the executive vice president owned 21,152 shares of the company’s stock, valued at approximately $12,144,420.80. This trade represents a 1.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 54,420 shares of company stock worth $28,134,684. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Leerink Partners increased their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Argus increased their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. TD Cowen increased their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.